Downregulated Dicer expression predicts poor prognosis in chronic lymphocytic leukemia. 2012

Dan-Xia Zhu, and Lei Fan, and Rui-Nan Lu, and Cheng Fang, and Wen-Yi Shen, and Zhi-Jian Zou, and Yin-Hua Wang, and Hua-Yuan Zhu, and Kou-Rong Miao, and Peng Liu, and Wei Xu, and Jian-Yong Li
Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the western world. Alterations in microRNAs (miRNAs) expression have been proposed to play a role in CLL pathogenesis. Dicer and Drosha are the main regulators of miRNA biogenesis, and deregulation of their expression has been indicated as a possible cause of miRNA alterations observed in various cancers. To investigate the role of Dicer and Drosha in CLL, we assessed the expression of Dicer and Drosha and their correlation with other prognostic factors, including Binet stages, immunoglobulin heavy chain variable gene (IGHV) mutation status, TP53 mutation status, ZAP-70 protein and CD38 expression level in 165 CLL patients by using real-time polymerase chain reaction methods. Patients with unmutated IGHV genes had significantly lower expression of Dicer than patients with IGHV mutations. The lower expression level of Dicer was also significantly associated with higher level of CD38 and ZAP-70, and more aggressive Binet stage. We also analyzed Dicer expression in different cytogenetic subgroups. Lower Dicer level was found in patients with unfavorable cytogenetic aberrations (deletion in 17p13 or 11q22.3) in contrast to higher level in good risk cytogenetics (deletion in 13q14 as the sole abnormality). Furthermore, the lower expression of Dicer in CLL shows a strong association with shorter overall survival (OS) (P = 0.0046) as well as with reduced treatment free survival (TFS) (P = 0.0006). By contrast, no differences in the expression of Drosha among these groups of patients were observed. Our data suggest that Dicer expression may play an important role in the progression and prognosis of CLL.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002869 Chromosome Aberrations Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS. Autosome Abnormalities,Cytogenetic Aberrations,Abnormalities, Autosome,Abnormalities, Chromosomal,Abnormalities, Chromosome,Chromosomal Aberrations,Chromosome Abnormalities,Cytogenetic Abnormalities,Aberration, Chromosomal,Aberration, Chromosome,Aberration, Cytogenetic,Aberrations, Chromosomal,Aberrations, Chromosome,Aberrations, Cytogenetic,Abnormalities, Cytogenetic,Abnormality, Autosome,Abnormality, Chromosomal,Abnormality, Chromosome,Abnormality, Cytogenetic,Autosome Abnormality,Chromosomal Aberration,Chromosomal Abnormalities,Chromosomal Abnormality,Chromosome Aberration,Chromosome Abnormality,Cytogenetic Aberration,Cytogenetic Abnormality
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D015451 Leukemia, Lymphocytic, Chronic, B-Cell A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease. B-Cell Leukemia, Chronic,B-Lymphocytic Leukemia, Chronic,Chronic Lymphocytic Leukemia,Leukemia, B-Cell, Chronic,Leukemia, Lymphocytic, Chronic,Lymphocytic Leukemia, Chronic, B-Cell,Lymphoma, Small Lymphocytic,B-Cell Chronic Lymphocytic Leukemia,B-Cell Malignancy, Low-Grade,Diffuse Well-Differentiated Lymphocytic Lymphoma,Disrupted In B-Cell Malignancy,Leukemia, B Cell, Chronic,Leukemia, Chronic Lymphatic,Leukemia, Chronic Lymphocytic,Leukemia, Chronic Lymphocytic, B-Cell,Leukemia, Lymphoblastic, Chronic,Leukemia, Lymphocytic, Chronic, B Cell,Lymphoblastic Leukemia, Chronic,Lymphocytic Leukemia, Chronic,Lymphocytic Leukemia, Chronic, B Cell,Lymphocytic Lymphoma,Lymphocytic Lymphoma, Diffuse, Well Differentiated,Lymphocytic Lymphoma, Diffuse, Well-Differentiated,Lymphocytic Lymphoma, Well Differentiated,Lymphocytic Lymphoma, Well-Differentiated,Lymphoma, Lymphocytic,Lymphoma, Lymphocytic, Diffuse, Well Differentiated,Lymphoma, Lymphocytic, Diffuse, Well-Differentiated,Lymphoma, Lymphocytic, Well Differentiated,Lymphoma, Lymphocytic, Well-Differentiated,Lymphoma, Lymphoplasmacytoid, CLL,Lymphoma, Small Lymphocytic, Plasmacytoid,Lymphoma, Small-Cell,Lymphoplasmacytoid Lymphoma, CLL,Small-Cell Lymphoma,B Cell Chronic Lymphocytic Leukemia,B Cell Leukemia, Chronic,B Cell Malignancy, Low Grade,B Lymphocytic Leukemia, Chronic,B-Cell Leukemias, Chronic,B-Cell Malignancies, Low-Grade,B-Lymphocytic Leukemias, Chronic,CLL Lymphoplasmacytoid Lymphoma,CLL Lymphoplasmacytoid Lymphomas,Chronic B-Cell Leukemia,Chronic B-Cell Leukemias,Chronic B-Lymphocytic Leukemia,Chronic B-Lymphocytic Leukemias,Chronic Lymphatic Leukemia,Chronic Lymphatic Leukemias,Chronic Lymphoblastic Leukemia,Chronic Lymphoblastic Leukemias,Chronic Lymphocytic Leukemias,Diffuse Well Differentiated Lymphocytic Lymphoma,Disrupted In B Cell Malignancy,Leukemia, Chronic B-Cell,Leukemia, Chronic B-Lymphocytic,Leukemias, Chronic B-Cell,Leukemias, Chronic B-Lymphocytic,Leukemias, Chronic Lymphatic,Leukemias, Chronic Lymphoblastic,Low-Grade B-Cell Malignancies,Low-Grade B-Cell Malignancy,Lymphatic Leukemia, Chronic,Lymphatic Leukemias, Chronic,Lymphoblastic Leukemias, Chronic,Lymphocytic Leukemias, Chronic,Lymphocytic Lymphoma, Small,Lymphocytic Lymphomas,Lymphocytic Lymphomas, Small,Lymphocytic Lymphomas, Well-Differentiated,Lymphoma, CLL Lymphoplasmacytoid,Lymphoma, Small Cell,Lymphoma, Well-Differentiated Lymphocytic,Lymphomas, CLL Lymphoplasmacytoid,Lymphomas, Lymphocytic,Lymphomas, Small Lymphocytic,Lymphomas, Small-Cell,Lymphomas, Well-Differentiated Lymphocytic,Lymphoplasmacytoid Lymphomas, CLL,Malignancies, Low-Grade B-Cell,Malignancy, Low-Grade B-Cell,Small Cell Lymphoma,Small Lymphocytic Lymphoma,Small Lymphocytic Lymphomas,Small-Cell Lymphomas,Well-Differentiated Lymphocytic Lymphoma,Well-Differentiated Lymphocytic Lymphomas

Related Publications

Dan-Xia Zhu, and Lei Fan, and Rui-Nan Lu, and Cheng Fang, and Wen-Yi Shen, and Zhi-Jian Zou, and Yin-Hua Wang, and Hua-Yuan Zhu, and Kou-Rong Miao, and Peng Liu, and Wei Xu, and Jian-Yong Li
January 2022, Frontiers in immunology,
Dan-Xia Zhu, and Lei Fan, and Rui-Nan Lu, and Cheng Fang, and Wen-Yi Shen, and Zhi-Jian Zou, and Yin-Hua Wang, and Hua-Yuan Zhu, and Kou-Rong Miao, and Peng Liu, and Wei Xu, and Jian-Yong Li
June 2009, Clinical immunology (Orlando, Fla.),
Dan-Xia Zhu, and Lei Fan, and Rui-Nan Lu, and Cheng Fang, and Wen-Yi Shen, and Zhi-Jian Zou, and Yin-Hua Wang, and Hua-Yuan Zhu, and Kou-Rong Miao, and Peng Liu, and Wei Xu, and Jian-Yong Li
June 2013, Leukemia & lymphoma,
Dan-Xia Zhu, and Lei Fan, and Rui-Nan Lu, and Cheng Fang, and Wen-Yi Shen, and Zhi-Jian Zou, and Yin-Hua Wang, and Hua-Yuan Zhu, and Kou-Rong Miao, and Peng Liu, and Wei Xu, and Jian-Yong Li
January 2018, Cancer biomarkers : section A of Disease markers,
Dan-Xia Zhu, and Lei Fan, and Rui-Nan Lu, and Cheng Fang, and Wen-Yi Shen, and Zhi-Jian Zou, and Yin-Hua Wang, and Hua-Yuan Zhu, and Kou-Rong Miao, and Peng Liu, and Wei Xu, and Jian-Yong Li
February 2024, International journal of laboratory hematology,
Dan-Xia Zhu, and Lei Fan, and Rui-Nan Lu, and Cheng Fang, and Wen-Yi Shen, and Zhi-Jian Zou, and Yin-Hua Wang, and Hua-Yuan Zhu, and Kou-Rong Miao, and Peng Liu, and Wei Xu, and Jian-Yong Li
September 2018, European review for medical and pharmacological sciences,
Dan-Xia Zhu, and Lei Fan, and Rui-Nan Lu, and Cheng Fang, and Wen-Yi Shen, and Zhi-Jian Zou, and Yin-Hua Wang, and Hua-Yuan Zhu, and Kou-Rong Miao, and Peng Liu, and Wei Xu, and Jian-Yong Li
January 2006, Blood,
Dan-Xia Zhu, and Lei Fan, and Rui-Nan Lu, and Cheng Fang, and Wen-Yi Shen, and Zhi-Jian Zou, and Yin-Hua Wang, and Hua-Yuan Zhu, and Kou-Rong Miao, and Peng Liu, and Wei Xu, and Jian-Yong Li
September 2003, American journal of hematology,
Dan-Xia Zhu, and Lei Fan, and Rui-Nan Lu, and Cheng Fang, and Wen-Yi Shen, and Zhi-Jian Zou, and Yin-Hua Wang, and Hua-Yuan Zhu, and Kou-Rong Miao, and Peng Liu, and Wei Xu, and Jian-Yong Li
October 2004, Annals of oncology : official journal of the European Society for Medical Oncology,
Dan-Xia Zhu, and Lei Fan, and Rui-Nan Lu, and Cheng Fang, and Wen-Yi Shen, and Zhi-Jian Zou, and Yin-Hua Wang, and Hua-Yuan Zhu, and Kou-Rong Miao, and Peng Liu, and Wei Xu, and Jian-Yong Li
October 2015, JAMA oncology,
Copied contents to your clipboard!